Exhibit EX-99

Reed Elsevier, the global professional information company, reports continued underlying growth in revenue, operating profit and earnings in 2013.

•

Underlying revenue growth +2% (+3% excluding biennial exhibition cycling) to £6,035m/€7,121m

•

Adjusted EPS +9% to 54.0p for Reed Elsevier PLC; +5% to €0.99 for Reed Elsevier NV; +7% constant currency

•

Full year dividend +7% to 24.60p for Reed Elsevier PLC; +8% to €0.506 for Reed Elsevier NV

•

Reported EPS +9% to 48.8p for Reed Elsevier PLC; +5% to €0.91 for Reed Elsevier NV

•

Cash conversion rate 97%; leverage 2.1x net debt/ EBITDA pensions and lease adjusted (1.6x unadjusted) —

•

Continued underlying revenue and profit growth across all five major business areas

•

Improved profitability driven by process innovation and portfolio development

•

Improved business profile: electronic & face-to-face 81% (2012: 79%); growing at +5% to +7% underlying

•

£600m of share buybacks completed in 2013; total of £600m share buybacks planned in 2014 —

Commenting on the results, Anthony Habgood, Chairman, said:
“Reed Elsevier is continuing to deliver on its long term strategic and financial priorities. With underlying revenue growth across all major business areas, operating profit and earnings grew well in 2013. We made good progress on organic development and portfolio reshaping, and our strong cash flow enabled us to step up our share buyback programme whilst maintaining balance sheet strength. We are recommending a +7% increase in the full year dividend for Reed Elsevier PLC and +8% for Reed Elsevier NV, in line with growth in adjusted earnings per share at constant exchange rates.”

Chief Executive Officer, Erik Engstrom, commented:
“In 2013 we remained focused on transforming our business profile and improving the quality of our earnings. We did this primarily through organic investment, supported by a small number of targeted acquisitions, and by exiting from several businesses that no longer fit our strategy.”

“We continued to take a pragmatic approach to ensuring that the value compounding within the business translates into shareholder value, and as part of this we increased our share buyback programme to £600m in 2013. In 2014 we again intend to deploy a total of £600m on share buybacks, reflecting our strong balance sheet and cash flow.”

“Early trends across our business in 2014 remain broadly consistent with 2013, and we are confident that, by continuing to execute on our strategy, we will deliver another year of underlying revenue, profit, and earnings growth“.

Reed Elsevier continued to make good progress against its strategic and financial priorities in 2013.

Revenue of £6,035m/€7,121m; underlying growth +2% (+3% excluding biennial exhibition cycling): The overall underlying growth rate of +3% reflects +5 to +7% growth in electronic and face-to-face revenues, which now account for 81% of the total (2012: 79%), partially offset by continuing print revenue declines.

Adjusted operating profit £1,749m/€2,064m; underlying growth +5%: Underlying operating profit growth across Reed Elsevier reflects a combination of process innovation and portfolio development. Reported operating profit, after amortisation of acquired intangible assets, was up +3% to £1,376m/down -1% to €1,624m.

Return on invested capital 12.1%, up by 0.4%pts on 2012: The ROIC increase was driven by the increase in adjusted operating profit.

Interest and tax: Adjusted net interest expense was £39m lower at £177m (€56m lower at €209m) reflecting the benefits of term debt refinancing initiatives over the last 18 months. The adjusted effective tax rate was unchanged at 23.5%.

Adjusted EPS up +9% to 54.0p for Reed Elsevier PLC; up +5% to €0.99 for Reed Elsevier NV; constant currency growth +7%: Reported EPS growth was +9% to 48.8p for Reed Elsevier PLC, +5% to €0.91 for Reed Elsevier NV.

Equalised full year dividend up +7% to 24.60p for Reed Elsevier PLC; up +8% to €0.506 for Reed Elsevier NV: The proposed average full year dividend growth rate is in line with adjusted EPS growth at constant currency rates. The proposed final dividend for Reed Elsevier PLC is up +6% to 17.95p following an +11% increase in the interim dividend. The proposed final dividend for Reed Elsevier NV is up +11% to €0.374, following a +2% increase in the interim dividend. The difference in interim and final dividend growth rates reflects exchange rate movements between the declaration dates. The Reed Elsevier PLC and Reed Elsevier NV full year dividends are covered 2.2x and 2.0x by adjusted EPS respectively.

Net debt / EBITDA 2.1x on a pensions and lease adjusted basis (unadjusted 1.6x): Net debt was £3.1bn/€3.7bn on 31 December 2013. Capital expenditure remained at 5% of revenues. The adjusted operating cash flow conversion rate was 97%.

Organic development: In 2013 we continued to develop our global technology platforms across the business, launch new products and services in both existing and adjacent market segments, and extend our reach in high growth markets and geographies.

Acquisitions & disposals: In 2013 we completed 20 small acquisitions of content and data assets across all market segments for a total consideration of £230m. We also completed the disposal of 26 assets that no longer fit our strategy, for a total consideration of £331m.

Share buybacks: In 2013 we deployed £600m on share buybacks. In 2014, although we currently expect disposal proceeds to be lower, we again intend to deploy a total of £600m on share buybacks, based on our strong balance sheet and cash flow. £100m of this year’s total has already been completed.

2014 OUTLOOK
Early trends across our business in 2014 remain broadly consistent with full year 2013, with some small variations by market and geography. We are confident that, by continuing to execute on our strategy of delivering improved outcomes to our professional customers, primarily through organic investment, we will deliver another year of underlying revenue, profit, and earnings growth in 2014.
REED ELSEVIER FINANCIAL SUMMARY


				£								€
	Year ended 31 December								Year ended 31 December
																		Underlying
	2013			2012†					2013			2012†						growth
£m£mChange									€	m		€	m		Change			rates

Revenue		6,035			6,116		-1	%		7,121			7,523			-5	%		+2%/+3	%*

Adjusted operating profit		1,749			1,688		+4	%		2,064			2,076			-1	%		+5	%
Adjusted operating margin		*29.0*	%		27.6	%				*29.0*	%		27.6	%

Adjusted net interest expense		(177	)		(216	)				(209	)		(265	)

Adjusted profit before tax		1,572			1,472		+7	%		1,855			1,811			+2	%

Tax		(370	)		(346	)				(436	)		(426	)
Minority interests		(5	)		(5	)				(6	)		(6	)

Adjusted net profit		1,197			1,121		+7	%		1,413			1,379			+2	%

Reported net profit		1,110			1,044					1,310			1,284

Net borrowings		3,072			3,127					3,686			3,846

Reed Elsevier PLC

Reed Elsevier NV

Year ended 31 December

2013

2012†

2013

2012†

Change at constant

pence

pence

Change

€

Change

currencies

Adjusted earnings per share

54.0p

49.4p

+9%

€0.99

€0.94

+5%

+7%

Reported earnings per share

48.8p

44.8p

+9%

€0.91

€0.87

+5%

Ordinary dividend per share

24.6p

23.0p

+7%

€0.506

€0.467

+8%

Adjusted and underlying figures are additional performance measures used by management. Reconciliations between the reported and adjusted figures are set out in note 4 to the combined financial information on page 28. The reported operating profit figures are set out in note 2 on page 25. Unless otherwise indicated, all percentage movements in the following commentary refer to performance at constant exchange rates. Underlying growth rates are calculated at constant currencies, and exclude the results of all acquisitions and disposals made in both the year and prior year and assets held for sale. Constant currency growth rates are based on 2012 full year average and hedge exchange rates.

†

Comparative financial information has been restated following the adoption of IAS19 Employee Benefits (revised), see note 1 to the combined financial information on page 23.

FORWARD-LOOKING STATEMENTS
This Results Announcement contains forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. These statements are subject to a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those currently being anticipated. The terms “outlook”, “estimate”, “project”, “plan”, “intend”, “expect”, “should be”, “will be”, “believe” and similar expressions identify forward-looking statements. Factors which may cause future outcomes to differ from those foreseen in forward-looking statements include, but are not limited to, competitive factors in the industries in which Reed Elsevier operates; demand for Reed Elsevier’s products and services; exchange rate fluctuations; general economic and business conditions; legislative, fiscal, tax and regulatory developments and political risks; the availability of third party content and data; breaches of our data security systems and interruptions in our information technology systems; changes in law and legal interpretations affecting Reed Elsevier’s intellectual property rights and other risks referenced from time to time in the filings of Reed Elsevier with the US Securities and Exchange Commission.


				£								€
	Year ended 31 December								Year ended 31 December
																					Underlying
	2013			2012†					2013			2012†						Change at constant			growth
£m£mChange									€	m		€	m		Change			currencies			rates

Revenue
Scientific, Technical & Medical		2,126			2,063		+3	%		2,509			2,538			-1	%		+1	%		+2	%
Risk Solutions		933			926		+1	%		1,101			1,139			-3	%		-1	%		+8	%
Business Information		547			663		-17	%		645			815			-21	%		-19	%		+4	%
Legal		1,567			1,610		-3	%		1,849			1,980			-7	%		-4	%		+1	%
Exhibitions		862			854		+1	%		1,017			1,051			-3	%		+2	%		+2%/+7	%*
		6,035			6,116		-1	%		7,121			7,523			-5	%		-3	%		+2%/+3	%*

Adjusted operating profit
Scientific, Technical & Medical		826			780		+6	%		975			960			+2	%		+2	%		+3	%
Risk Solutions		414			392		+6	%		489			482			+1	%		+4	%		+8	%
Business Information		107			119		-10	%		126			146			-14	%		-11	%		+14	%
Legal		238			234		+2	%		281			288			-2	%		+1	%		+5	%
Exhibitions		213			210		+1	%		251			258			-3	%		+4	%		+4	%
Unallocated items		(49	)		(47	)				(58	)		(58	)

		1,749			1,688		+4	%		2,064			2,076			-1	%		+1	%		+5	%

†

Comparative financial information has been restated following the adoption of IAS19 Employee Benefits (revised), see note 1 to the combined financial information on page 23.

Following a review of activities, assets and costs across the business, Reed Elsevier will introduce a new method for the allocation of corporate and shared costs from January 2014. Previously unallocated items will be attributed to the business areas, as will costs relating to shared activities and resources, on the basis of usage and benefits derived. This new allocation reflects an increased level of shared resources and capitalised costs. Had this new method of allocation been applied during 2013, it would have resulted in the adjusted operating profit figures shown below:

Based on the new methodology for allocation of corporate and shared costs 2013 margin would have been 37.0%. See page 5

Strong volume growth in primary research submissions and usage, and in databases & tools, across the scientific, technical and medical segments. Electronic revenues, which now account for 72% of the total, grew strongly across all segments. Print book sales and pharma promotion continued to decline.

Underlying revenues grew +2% and underlying adjusted operating profits grew +3%.

In primary research, growth in article submissions and usage remained strong across the scientific, technical and medical segments, and journal quality, as measured by Impact Factor, continued to improve. Revenue growth was driven by solid subscription renewals and new sales. “Author pays” or “author’s funder pays” article volumes continued to grow strongly from a small base. Good growth in scientific databases & tools and electronic clinical solutions was also supported by strong new sales.

Print book sales and pharma promotion continued to decline reflecting a combination of format migration and structural changes in the pharmaceutical industry.

Portfolio development continued in 2013. Disposals included Elsevier Business Intelligence and a number of small print and pharma focused assets. We supported our organic growth strategy with small targeted acquisitions, including Mendeley, an online reference management and collaboration solution.

2014 outlook: The customer environment remains broadly unchanged on last year, with variations by geography and customer segment. We expect continued volume growth and strong demand for electronic products and solutions, and continued declines in print book and pharma promotion revenues. Overall we expect another year of modest underlying revenue growth in 2014.

Based on the new methodology for allocation of corporate and shared costs 2013 margin would have been 43.0%. See page 5

All business segments achieved strong growth in 2013. The improvement in adjusted operating margin largely reflects the impact of portfolio changes, as underlying cost growth was in line with underlying revenue growth, reflecting continued new product development.

Underlying revenues grew +8% and underlying adjusted operating profits grew +8%.

Revenue growth in the insurance segment was driven by good take up of new products and services across the insurance workflow, expansion into adjacent market verticals, and volume growth in the core underwriting business. The expansion into international markets is progressing well, although the absolute revenue contribution remains small relative to Risk Solutions overall.

Business Services growth reflected strong demand for identity authentication and fraud detection solutions across markets. The US mortgage refinancing market did slow down in the second half as expected, but the impact of this was largely offset by continued good growth elsewhere.

New product sales drove strong growth in Government revenues for the year, somewhat tempered by a slowdown in federal markets in the fourth quarter.

The 2013 results reflect the impact of portfolio changes, including the disposal of the pre-employment screening business in H1, and some small acquisitions, including Mapflow and Enclarity. Taken together, portfolio changes had the effect of reducing reported revenues but increasing the adjusted operating profit margin, with underlying cost growth broadly matching revenue growth.

2014 outlook: The outlook for the federal government segment and mortgage refinancing market is uncertain, but the fundamental growth drivers of the Risk Solutions business remain strong. We will continue to invest in new products that leverage our leading content and analytics expertise, and to extend our services in new verticals and geographies. Overall we expect good underlying revenue growth across market segments.

Based on the new methodology for allocation of corporate and shared costs 2013 margin would have been 19.3%. See page 5

Underlying revenue growth accelerated in 2013 reflecting continued good growth in data services and modest growth elsewhere. Focus on process innovation drove a further improvement in adjusted operating profit margin.

Underlying revenues grew +4%, and underlying adjusted operating profits grew +14%.

Major Data Services, which now accounts for over 50% of continuing portfolio revenue, achieved strong growth in 2013 driven by Accuity, ICIS and XpertHR.

Leading Brands and Other Business Magazines & Services achieved modest growth, despite weak print advertising markets, with solid results from data solutions and the agricultural segments.

The improvement in adjusted operating profit margin in the year was entirely the result of the continued organic transformation of the business.

In 2013 we continued to exit from businesses that no longer fit our strategy, with disposals during the period including RBI Australia, Italy, and France. Since the beginning of this year we have also divested BuyerZone in the Marketing Services segment.

Since bringing the management structure of Business Information and Risk Solutions more closely together at the end of 2012 we have made good initial progress on leveraging Risk Solutions’ strength in data, analytics and technology across Business Information’s broader geographic footprint.

2014 outlook: We expect continued good underlying growth in Major Data Services and stable Leading Brands and Other Business Magazines & Services.

Based on the new methodology for allocation of corporate and shared costs 2013 margin would have been 15.9%. See page 5

Positive underlying revenue growth was maintained in 2013 despite subdued market conditions in the US and Europe. Electronic revenues continued to show good growth, largely offset by print declines.

In the US and in our major European markets, conditions remained subdued, with growth in online solutions largely offset by continued print declines. Other international markets achieved good growth.

The roll out of new product releases continued, with 73% of US legal customers activated on the New Lexis platform at period end, and new product usage progressing well.

Ongoing process innovation and some initial decommissioning of old infrastructure more than offset inflation and higher depreciation, contributing to a 0.7 percentage point margin improvement in 2013.

The 2013 results reflect the impact of portfolio reshaping over the last 18 months, including the disposal of the US document retrieval and filing business in late 2012 and other small print assets early in 2013. In the second half of 2013 LexisNexis Martindale Hubbell, the US lawyer directory, was spun out into a joint venture with Internet Brands, a broad-based internet marketing firm.

2014 outlook: We will continue the roll out of our new technology platforms and products in 2014, and will maintain our focus on process improvement. Our customer markets remain subdued, however, limiting the scope for underlying revenue growth.

Based on the new methodology for allocation of corporate and shared costs 2013 margin would have been 24.4%. See page 5

In 2013 Exhibitions maintained strong underlying revenue growth of +7% excluding the effect of biennial show cycling. While growth in Europe was modest, the US, Japan, Brazil and other markets all grew well.

Underlying revenues grew +2% (+7% excluding biennial cycling), and underlying adjusted operating profits
grew +4%.

The US and Japan achieved strong revenue growth for the year. US shows reported good growth in visitor numbers, and growth in Japan was supported by leadership of the alternative energy sector and new launches. Brazil and China continued to generate strong growth.

In Europe good growth in international events more than offset softness in some domestic continental European events, resulting in modest overall growth.

In 2013 we launched 37 new events, primarily in high growth geographies and sectors, including the highly successful launch of World Travel Market Latin America, building on a global franchise.

We undertook a number of portfolio changes during the year, with acquisitions including Expo Ferretera in Mexico, IPSA in Russia, Travelweek São Paulo in Brazil and Capsule in the US. Disposals include a number of Spanish events as well as some smaller events across geographies.

The impact of biennial exhibition cycling has steadily been reduced from 10% in 2011 through 8% in 2012, to 5% in 2013.

2014 outlook: We expect good underlying growth in the US and Japan, and limited growth in Europe. In other markets we expect growth to remain strong, albeit at a slightly lower rate than in 2013. In 2014, which is a “cycling-in” year, we expect the impact of cycling to be further reduced to around 2 percentage points of growth.


				£								€
	Year ended 31 December								Year ended 31 December
	2013			2012†					2013			2012†						Change at constant			Underlying growth
£m£mChange									€	m		€	m		Change			currencies			rates
Adjusted figures
Revenue		6,035			6,116		-1	%		7,121			7,523			-5	%		-3	%		+2%/+3%	*
Operating profit		1,749			1,688		+4	%		2,064			2,076			-1	%		+1	%		+5	%
Operating margin		*29.0*	%		27.6	%				*29.0*	%		27.6	%
Profit before tax		1,572			1,472		+7	%		1,855			1,811			+2	%		+4	%
Net profit		1,197			1,121		+7	%		1,413			1,379			+2	%		+4	%
Net margin		*19.8*	%		18.3	%				*19.8*	%		18.3	%
Operating cash flow		1,703			1,603		+6	%		2,010			1,972			+2	%		+4	%
Operating cash flow conversion		97	%		95	%				97	%		95	%

†

Comparative financial information has been restated following the adoption of IAS19 Employee Benefits (revised), see note 1 to the combined financial information on page 23. Reed Elsevier uses adjusted figures as additional performance measures. Adjusted figures primarily exclude items related to acquisitions and disposals, and the associated deferred tax movements. Reconciliations between the reported and adjusted figures are set out in note 4 to the combined financial information on page 28.

Underlying revenue growth was +2%, or +3% excluding the effects of biennial event cycling in our exhibitions business. Reported revenue was £6,035m/€7,121m (2012: £6,116m/€7,523m), down -1% expressed in sterling and down -5% in euros.

The overall impact of disposals in 2013 was to reduce revenues by -6%, partially offset by a +1% increase from acquisitions. There have been disposals in each of our businesses, but the effect is most significant in Risk Solutions, where we sold the pre-employment screening business, in Business Information where we made a number of disposals, and in Legal where Martindale Hubbell, the US lawyer directory business, was spun out into a joint venture. Disposals made throughout 2013 will continue to impact reported revenues and operating profit growth rates in 2014.

The impact of currency movements was to increase revenues expressed in sterling by +2%, principally due to the strengthening of the US dollar, on average, against sterling. Currency effects reduced revenues expressed in euros by -2%, principally due to the weakening of the US dollar against the euro.

Underlying adjusted operating profit grew +5%. Total adjusted operating profit was £1,749m/€2,064m (2012: £1,688m/€2,076m), up +4% expressed in sterling and down -1% in euros. The impact of disposals was to reduce adjusted operating profit by -4%. Currency effects increased adjusted operating profit by +3% expressed in sterling and reduced adjusted operating profit by -2% in euros.

Underlying costs were up +2%, reflecting investment in global technology platforms and launching of new products and services, partly offset by continued process improvements. Actions were taken across our businesses, especially Legal, to improve cost efficiency. Total operating costs, including acquisitions and disposals, decreased by -3% expressed in sterling and -7% in euros.

The net pension expense, excluding the net pension financing charge, was £61m/€72m (2012: £89m/€109m), including settlement and past service credits of £59m/€70m (2012: £20m/€25m), mainly arising from benefits changes in the US, which will reduce future costs for our US businesses.

The overall adjusted operating margin of 29.0% was 1.4 percentage points higher than in the prior year. This included a 0.5 percentage point benefit to margin from portfolio changes as well as a 0.3 percentage point benefit from currency effects.

Interest expense was £177m/€209m (2012: £216m/€265m). The reduction primarily reflects the benefit of term debt refinancing at lower rates.

Adjusted profit before tax was £1,572m/€1,855m (2012: £1,472m/€1,811m), up +7% expressed in sterling and +2%
in euros, and up +4% at constant currencies, reflecting the increase in adjusted operating profits and lower
interest expense.

The adjusted effective tax rate on adjusted profit before tax was 23.5%, in line with the prior year. The effective tax rate excludes movements in deferred taxation assets and liabilities related to goodwill and acquired intangible assets, and includes the benefit of tax amortisation where available on those items. Adjusted operating profits and taxation are grossed up for the equity share of taxes in joint ventures.

The application of tax law and practice is subject to some uncertainty and amounts are provided in respect of
this. Discussions with tax authorities relating to cross border transactions and other matters are ongoing. Although the outcome of these discussions cannot be predicted, no significant impact on the financial position of Reed Elsevier is expected.

The adjusted net profit attributable to shareholders of £1,197m/€1,413m (2012: £1,121m/€1,379m) was up +7% expressed in sterling and up +2% in euros, and up +4% at constant currencies.


				£								€
	Year ended 31 December								Year ended 31 December
	2013			2012†					2013			2012†						Change at constant
£m£mChange									€	m		€	m		Change			currencies
Reported figures
Operating profit		1,376			1,333		+3	%		1,624			1,639			-1	%		+1	%
Profit before tax		1,196			1,151		+4	%		1,412			1,416			0	%		+2	%
Net profit		1,110			1,044		+6	%		1,310			1,284			+2	%		+3	%
Net margin		*18.4*	%		17.1	%				*18.4*	%		17.1	%

†

Comparative financial information has been restated following the adoption of IAS19 Employee Benefits (revised), see note 1 to the combined financial information on page 23.

Reported operating profit, after amortisation of acquired intangible assets and acquisition related costs, was £1,376m/€1,624m (2012: £1,333m/€1,639m).

The amortisation charge in respect of acquired intangible assets, including the share of amortisation in joint ventures, amounted to £318m/€375m (2012: £329m/€405m). Acquisition related costs were £43m/€51m (2012: £21m/€26m), including a charge for certain deferred consideration payments required to be expensed
under IFRS.

The reported profit before tax was £1,196m/€1,412m (2012: £1,151m/€1,416m).

Reported net finance costs include a charge of £19m/€22m (2012: £11m/€14m) in respect of the defined benefit pension schemes. Net pre-tax disposal gains were £16m/€19m (2012: £45m/€56m) arising largely from the sale of Risk Solutions’ pre-employment screening business. These were offset by a related tax charge of £34m/€40m (2012: credit of £58m/€71m).

The reported tax charge was £81m/€96m (2012: £102m/€126m). This included a deferred tax credit of £221m/€261m arising on the alignment of certain business assets with their global management structure. The reported net profit attributable to the parent companies’ shareholders was £1,110m/€1,310m (2012: £1,044m/€1,284m).

Adjusted operating cash flow was £1,703m/€2,010m (2012: £1,603m/€1,972m), up +6% expressed in sterling, up +2% in euros and up +4% at constant currencies. Adjusted operating cash flow conversion was 97% (2012: 95%).

Capital expenditure was £308m/€363m (2012: £333m/€409m), including £251m/€296m (2012: £263m/€323m) in respect of capitalised development costs. This reflects sustained investment in new products and related infrastructure, particularly in the Legal business. Depreciation and amortisation of capitalised development costs were £249m/€294m (2012: £227m/€279m). Capital expenditure was 5.1% of revenue (2012: 5.5%). Depreciation and amortisation were 4.1% of revenue (2012: 3.7%).

Free cash flow – after interest and taxation – was £1,161m/€1,371m (2012: £1,098m/€1,351m) before acquisition related spend and cash flows relating to prior year exceptional restructuring programmes. Cash taxes paid were £347m/€409m (2012: £281m/€346m), reflecting increased taxable profits, predominantly in the US.

Payments made in respect of acquisition related costs amounted to £28m/€33m (2012: £37m/€45m). Payments for exceptional restructuring programmes from prior years were £12m/€14m (2012: £25m/€30m), principally property costs. Tax recovered in respect of acquisition related and exceptional restructuring costs amounted to £10m/€12m (2012: £39m/€48m).

Free cash flow before dividends was £1,131m/€1,336m (2012: £1,075m/€1,324m). Ordinary dividends paid to shareholders in the year, being the 2012 final and 2013 interim dividends, amounted to £549m/€648m (2012: £521m/€641m). Free cash flow after dividends was £582m/€688m (2012: £554m/€683m).

Cash spent on acquisitions was £221m/€261m (2012: £316m/€389m), including deferred consideration of £21m/€25m (2012: £30m/€37m) on past acquisitions. Spend on venture capital investments was £10m/€12m (2012: £7m/€9m).

Total consideration from disposal transactions closed in 2013 was £331m, including £6m in respect of freehold properties. The net cash received in the calendar year from business disposals, after timing differences and separation and transaction costs, was £195m/€230m (2012: £160m/€197m). Net tax paid in respect of disposals was £25m/€30m (2012: tax recovered £26m/€32m).

Share repurchases by the parent companies in 2013 were £600m/€708m (2012: £250m/€308m) with a further £100m repurchased in 2014 as at 26 February. Proceeds from the exercise of share options were £125m/€148m (2012: £48m/€59m).

Net borrowings at 31 December 2013 were £3,072m/€3,686m, a decrease of £55m/€160m since 31 December 2012. The majority of our borrowings are denominated in US dollars and the strengthening of sterling and euro against the dollar since the start of the year resulted in slightly lower net borrowings when translated at year end rates. Excluding currency translation effects, net borrowings decreased by £27m/€33m. Expressed in US dollars, net borrowings at 31 December 2013 were $5,089m, in line with the prior year.

Gross borrowings after fair value adjustments at 31 December 2013 amounted to £3,281m/€3,937m (2012: £3,892m/€4,787m). The fair value of related derivative assets was £77m/€93m (2012: £124m/€153m). Cash balances have been reduced to £132m/€158m (2012: £641m/€788m), increasing the efficiency of our balance sheet.

The effective interest rate on gross borrowings was 4.8% in 2013, down from 5.6% in the prior year. As at 31 December 2013, after taking into account interest rate and currency derivatives, a total of 57% of Reed Elsevier’s gross borrowings were at fixed rates with a weighted average remaining life of 6.0 years.

The ratio of net debt to 12 months trailing EBITDA (adjusted earnings before interest, tax, depreciation and amortisation) as at 31 December 2013 was 2.1x (2012: 2.2x) on a pensions and lease adjusted basis. On an unadjusted basis net debt to EBITDA was 1.6x (2012: 1.7x).

During July 2013, Reed Elsevier’s committed bank facility, maturing in June 2015, was cancelled and replaced with a new $2,000m facility, maturing in July 2018. This back-up facility provides security of funding for short term debt issuance and is undrawn.

In March 2013, $309m of US dollar denominated fixed rate term debt maturing in January 2019, with a coupon of 8.625%, was exchanged for $389m of the 3.125% term debt due in 2022 and cash. In June 2013, $282m of Swiss franc denominated fixed rate term debt due in 2018 was issued at a coupon of 1.0%.

In December 2013, $461m of US term debt maturing in January 2014 was redeemed, taking advantage of the make-whole election.

Reed Elsevier has ample liquidity and access to debt capital markets, providing the ability to repay or refinance borrowings as they mature and to fund ongoing operational requirements.

Gross capital employed at 31 December 2013 was £11,155m/€13,386m (2012: £11,338m/€13,946m) after adding back accumulated amortisation and impairment of acquired intangible assets and goodwill. The decrease of £183m in sterling principally reflects business divestments and currency effects. The decrease of €560m in euros reflects a more significant currency translation impact of the movement in the US dollar against the euro.

The post-tax return on average invested capital (“ROIC”) in the year was 12.1% (up 0.4 percentage points from 2012, as restated). The increase in the return reflects the improved trading performance.

Reed Elsevier PLC

Reed Elsevier NV

Year ended 31 December

Change at

2013

2012†

2013

2012†

constant

pence

pence

Change

€

Change

currencies

Reported earnings per share

48.8p

44.8p

+9%

€0.91

€0.87

+5%

Adjusted earnings per share

54.0p

49.4p

+9%

€0.99

€0.94

+5%

+7%

Ordinary dividend per share

24.6p

23.0p

+7%

€0.506

€0.467

+8%

†

Comparative financial information has been restated following the adoption of IAS19 Employee Benefits (revised), see note 1 to the combined financial information on page 23.

The reported earnings per share for Reed Elsevier PLC shareholders was 48.8p (2012: 44.8p) and for Reed Elsevier NV shareholders was €0.91 (2012: €0.87) reflecting the improved trading performance and deferred tax credits.

Adjusted earnings per share were up +9% at 54.0p (2012: 49.4p) and up +5% at €0.99 (2012: €0.94) for Reed Elsevier PLC and Reed Elsevier NV respectively. At constant currencies, the adjusted earnings per share of both companies increased by +7%.

The equalised final dividends declared by the respective boards are 17.95p per share for Reed Elsevier PLC and €0.374 per share for Reed Elsevier NV, up +6% and +11% respectively against the prior year final dividends. This gives total dividends for the year of 24.6p (2012: 23.0p) and €0.506 (2012: €0.467), up +7% and +8% respectively. The difference in growth rates in the final dividends, and the earlier interim dividends, reflects changes in the euro:sterling exchange rate since the respective prior year dividend announcement dates.

Dividend cover, based on adjusted earnings per share and the total interim and proposed final dividends for the year, is 2.2x (2012: 2.2x) for Reed Elsevier PLC and 2.0x (2012: 2.0x) for Reed Elsevier NV. The dividend policy of the parent companies is, subject to currency considerations, to grow dividends broadly in line with adjusted earnings per share whilst maintaining dividend cover (defined as the number of times the annual dividend is covered by the adjusted earnings per share) of at least two times over the longer term.

During the year, 41.9m Reed Elsevier PLC shares and 25.2m Reed Elsevier NV shares (including R shares) were repurchased, partially mitigating the earnings per share dilution from divestments. As at 31 December 2013, shares in issue for Reed Elsevier PLC and Reed Elsevier NV respectively amounted to 1,157.4m and 709.7m. A further 6.0m Reed Elsevier PLC shares and 3.5m Reed Elsevier NV shares have been repurchased in January and February 2014.

The principal risks facing Reed Elsevier arise from the highly competitive and rapidly changing nature of our markets, the increasingly technological nature of our products and services, the international nature of our operations, legislative, fiscal and regulatory developments, and economic conditions in our markets. Certain businesses could also be affected by the impact on publicly funded and other customers of changes in funding and by cyclical pressures on advertising and promotional spending or through the availability of alternative free sources of information.

The principal risks and uncertainties that have been identified, and are being addressed, are summarised below:

•

Demand for our products and services may be impacted by factors such as the economic environment in the US, Europe and other major economies, and government funding.

•

Our products and services are largely comprised of intellectual property content delivered through a variety of media. We rely on trademark, copyright, patent and other intellectual property laws to establish and protect our proprietary rights in these products and services. There is a risk that our proprietary rights could be challenged, limited, invalidated or circumvented which may impact demand for and pricing of our products

•

A number of our businesses rely extensively upon content and data from external sources. Data is obtained from public records, governmental authorities, customers and other information companies, including competitors. The disruption or loss of data sources, either because of changes in the law or because data suppliers decide not to supply them, could adversely affect our products and services.

•

Our scientific, technical & medical (STM) primary publications, like those of most of our competitors, are published largely on a paid subscription basis. There is debate in the government, academic and library communities, which are the principal customers for our STM publications, regarding whether such publications should be funded instead through fees charged to authors or authors’ funders and/or made freely available after a period following publication. If these methods of STM publishing are widely adopted or mandated, it could adversely affect our revenue from paid subscription publications.

•

Reed Elsevier’s businesses are dependent on the continued acceptance by our customers of our products and services and the value placed on them. Failure to meet evolving customer needs could impact demand for our products and consequently adversely affect our revenue.

•

Our businesses operate in highly competitive markets which continue to evolve in response to technological innovations, changing legislation, regulatory changes, the entrance of new competitors and other factors. Failure to anticipate market trends could impact the competitiveness of our products and services and consequently adversely affect our revenue.

•

We regularly make small acquisitions to strengthen our portfolio. If we are unable to generate the anticipated benefits such as revenue growth, synergies and/or cost savings associated with these acquisitions this could adversely affect return on invested capital and financial condition.

•

Our businesses are dependent on electronic platforms and networks, primarily the internet, for delivery of products and services. These could be adversely affected if our electronic delivery platforms or networks experience a significant failure, interruption, or security breach.

•

Our businesses maintain databases and information online, including personal information. Breaches of our data security or failure to comply with applicable legislation or regulatory or contractual requirements could damage our reputation and expose us to risk of loss or litigation and increased regulation.

•

Our organisational and operational structures are dependent on outsourced and offshored functions. Poor performance or failure of third parties to whom we have outsourced activities could adversely affect our business performance, reputation and financial condition.

•

The implementation and execution of our strategies and business plans depend on our ability to recruit, motivate and retain high quality people. We compete globally and across business sectors for talented management and skilled individuals, particularly those with technology and data analytics capabilities. An inability to recruit, motivate or retain such people could adversely affect our business performance.

•

We operate a number of pension schemes around the world. Historically, the largest schemes have been of the defined benefit type in the UK, the US and the Netherlands. The assets and obligations associated with those defined benefit pension schemes are sensitive to changes in the market values of assets and the market related assumptions used to value scheme liabilities. Adverse changes to inter alia asset values, discount rates or inflation could increase future pension costs and funding requirements.

•

Our businesses operate globally and our earnings are subject to taxation in many differing jurisdictions and at differing rates. We seek to organise our affairs in a tax efficient manner, taking account of the jurisdictions in which we operate. However, tax laws that apply to Reed Elsevier businesses may be amended by the relevant authorities or interpreted differently, which could adversely affect our reported results.

•

The Reed Elsevier combined financial statements are expressed in pounds sterling and are subject to movements in exchange rates on the translation of the financial information of businesses whose operational currencies are other than sterling. The US is our most important market and, accordingly, significant fluctuations in the US dollar exchange rate could significantly affect our reported results.

•

Macro economic, political and market conditions may also adversely affect the availability of short and long term funding, volatility of interest rates, currency exchange rates and inflation.

•

As a world leading provider of professional information solutions to the scientific, technical & medical, risk solutions & business information, legal, and exhibitions markets we are expected to adhere to high standards of independence and ethical conduct. A breach of generally accepted ethical business standards could adversely affect our business performance, reputation and financial condition.

•

Our businesses have an impact on the environment, principally through the use of energy and water, waste generation and, in our supply chain, through paper use and print and production technologies. Failure to manage our environmental impact could adversely affect our reputation.


				£						€
				2012						2012
2013Restated								2013		Restated
	£	m		£	m		€	m		€	m

Revenue		6,035			6,116			7,121			7,523
Cost of sales		(2,118	)		(2,139	)		(2,499	)		(2,631	)

Gross profit		3,917			3,977			4,622			4,892
Selling and distribution costs		(1,005	)		(1,015	)		(1,186	)		(1,249	)
Administration and other expenses		(1,565	)		(1,653	)		(1,847	)		(2,033	)

Operating profit before joint ventures		1,347			1,309			1,589			1,610
Share of results of joint ventures		29			24			35			29
Operating profit		1,376			1,333			1,624			1,639

Finance income		10			16			12			20
Finance costs		(206	)		(243	)		(243	)		(299	)

Net finance costs		(196	)		(227	)		(231	)		(279	)
Disposals and other non operating items		16			45			19			56
Profit before tax		1,196			1,151			1,412			1,416
Current tax		(352	)		(153	)		(416	)		(189	)
Deferred tax		271			51			320			63

Tax expense		(81	)		(102	)		(96	)		(126	)

Net profit for the year		1,115			1,049			1,316			1,290

Attributable to:
Parent companies’ shareholders		1,110			1,044			1,310			1,284
Non-controlling interests		5			5			6			6

Net profit for the year		1,115			1,049			1,316			1,290

Condensed combined statement of comprehensive income
For the year ended 31 December 2013


				£						€
				2012						2012
2013Restated								2013		Restated
	£	m		£	m		€	m		€	m

Net profit for the year		1,115			1,049			1,316			1,290
Items that will not be reclassified to profit or loss:
Actuarial gains/(losses) on defined benefit pension schemes		40			(293	)		47			(360	)
Tax on items that will not be reclassified to profit or loss		(24	)		96			(28	)		118

Total items that will not be reclassified to profit or loss		16			(197	)		19			(242	)

Items that may be reclassified subsequently to profit or loss:
Exchange differences on translation of foreign operations		(88	)		(136	)		(171	)		(102	)
Transfer to net profit on disposal of available for sale investments		–			11			–			14
Fair value movements on cash flow hedges		65			70			77			86
Transfer to net profit from cash flow hedge reserve (net of tax)		(2	)		21			(2	)		26
Tax on items that may be reclassified to profit or loss		(15	)		(19	)		(18	)		(24	)

Total items that may be reclassified to profit or loss		(40	)		(53	)		(114	)		–

Other comprehensive loss for the year		(24	)		(250	)		(95	)		(242	)

Total comprehensive income for the year		1,091			799			1,221			1,048

Attributable to:
Parent companies’ shareholders		1,086			794			1,215			1,042
Non-controlling interests		5			5			6			6

Total comprehensive income for the year		1,091			799			1,221			1,048


				£						€
	2013			2012			2013			2012
	£	m		£	m		€	m		€	m

Cash flows from operating activities
Cash generated from operations		1,943			1,847			2,293			2,272
Interest paid		(200	)		(231	)		(236	)		(284	)
Interest received		5			7			6			9
Tax paid (net)		(362	)		(216	)		(427	)		(266	)
Net cash from operating activities		1,386			1,407			1,636			1,731

Cash flows from investing activities
Acquisitions		(221	)		(316	)		(261	)		(389	)
Purchases of property, plant and equipment		(57	)		(70	)		(67	)		(86	)
Expenditure on internally developed intangible assets		(251	)		(263	)		(296	)		(323	)
Purchase of investments		(10	)		(7	)		(12	)		(9	)
Proceeds from disposals of property, plant and equipment		6			7			7			9
Gross proceeds from business disposals		311			235			367			289
Payments on business disposals		(116	)		(82	)		(137	)		(101	)
Dividends received from joint ventures		22			20			26			25

Net cash used in investing activities		(316	)		(476	)		(373	)		(585	)

Cash flows from financing activities
Dividends paid to shareholders of the parent companies		(549	)		(521	)		(648	)		(641	)
Distributions to non-controlling interests		(6	)		(4	)		(7	)		(5	)
Increase/(decrease) in short term bank loans, overdrafts and commercial paper		169			(434	)		199			(534	)
Issuance of term debt		184			592			217			728
Repayment of term debt		(915	)		(437	)		(1,080	)		(538	)
Repayment of finance leases		(10	)		(4	)		(12	)		(5	)
Disposal of non-controlling interests		–			7			–			9
Repurchase of ordinary shares		(600	)		(250	)		(708	)		(308	)
Proceeds on issue of ordinary shares		125			48			148			59
Net cash used in financing activities		(1,602	)		(1,003	)		(1,891	)		(1,235	)

Decrease in cash and cash equivalents		(532	)		(72	)		(628	)		(89	)

Movement in cash and cash equivalents
At start of year		641			726			788			871
Decrease in cash and cash equivalents		(532	)		(72	)		(628	)		(89	)
Exchange translation differences		23			(13	)		(2	)		6

At end of year		132			641			158			788


				£						€
	2013			2012			2013			2012
	£	m		£	m		€	m		€	m

Non-current assets
Goodwill		4,576			4,545			5,491			5,591
Intangible assets		3,124			3,275			3,749			4,028
Investments in joint ventures		125			100			150			123
Other investments		92			79			110			97
Property, plant and equipment		237			264			285			325
Deferred tax assets		442			79			530			97
Derivative financial instruments		64			138			77			170

		8,660			8,480			10,392			10,431

Current assets
Inventories and pre-publication costs		142			159			171			196
Trade and other receivables		1,416			1,380			1,699			1,697
Derivative financial instruments		124			57			149			70
Cash and cash equivalents		132			641			158			788

		1,814			2,237			2,177			2,751

Assets held for sale		21			297			25			365

Total assets		10,495			11,014			12,594			13,547

Current liabilities
Trade and other payables		2,595			2,544			3,114			3,129
Derivative financial instruments		4			11			5			14
Borrowings		648			730			778			898
Taxation		588			603			705			742
Provisions		17			30			20			37

		3,852			3,918			4,622			4,820

Non-current liabilities
Derivative financial instruments		13			–			16			–
Borrowings		2,633			3,162			3,159			3,889
Deferred tax liabilities		1,076			919			1,291			1,130
Net pension obligations		379			466			455			573
Provisions		116			139			139			171
		4,217			4,686			5,060			5,763

Liabilities associated with assets held for sale		3			96			4			118

Total liabilities		8,072			8,700			9,686			10,701

Net assets		2,423			2,314			2,908			2,846

Capital and reserves
Combined share capitals		224			223			269			274
Combined share premiums		2,887			2,727			3,464			3,354
Combined shares held in treasury		(1,464	)		(899	)		(1,757	)		(1,106	)
Translation reserve		(137	)		(23	)		25			161
Other combined reserves		880			252			867			121
Combined shareholders’ equity		2,390			2,280			2,868			2,804
Non-controlling interests		33			34			40			42

Total equity		2,423			2,314			2,908			2,846

Approved by the Boards of Reed Elsevier PLC and Reed Elsevier NV, 26 February 2014.

Condensed combined statement of changes in equity
For the year ended 31 December 2013


																						£
	Combined shareholders’ equity

	Combined share			Combined share			Combined shares						Other combined						Non-controlling			Total
	capitals			premiums			held in treasury			Translation reserve			reserves			Total			interests			Equity
	£	m		£	m		£	m		£	m		£	m		£	m		£	m		£	m

Balance at 1 January 2012		223			2,723			(663	)		88			(199	)		2,172			25			2,197
Total comprehensive income for the year		–			–			–			(136	)		930			794			5			799
Dividends paid		–			–			–			–			(521	)		(521	)		(4	)		(525	)
Issue of ordinary shares, net of expenses		1			47			–			–			–			48			–			48
Repurchase of ordinary shares		–			–			(250	)		–			–			(250	)		–			(250	)
Increase in share based remuneration reserve		–			–			–			–			31			31			–			31
Settlement of share awards		–			–			7			–			(7	)		–			–			–
Acquisitions		–			–			–			–			–			–			9			9
Disposal of non-controlling interests		–			–			–			–			6			6			1			7
Exchange differences on translation of capital and reserves		(1	)		(43	)		7			25			12			–			(2	)		(2	)

Balance at 1 January 2013		223			2,727			(899	)		(23	)		252			2,280			34			2,314
Total comprehensive income for the year		–			–			–			(88	)		1,174			1,086			5			1,091
Dividends paid		–			–			–			–			(549	)		(549	)		(6	)		(555	)
Issue of ordinary shares, net of expenses		1			124			–			–			–			125			–			125
Repurchase of ordinary shares		–			–			(600	)		–			–			(600	)		–			(600	)
Increase in share based remuneration reserve (net of tax)		–			–			–			–			48			48			–			48
Settlement of share awards		–			–			40			–			(40	)		–			–			–
Exchange differences on translation of capital and reserves		–			36			(5	)		(26	)		(5	)		–			–			–

Balance at 31 December 2013		224			2,887			(1,464	)		(137	)		880			2,390			33			2,423

Condensed combined statement of changes in equity
For the year ended 31 December 2013


																						€
	Combined shareholders’ equity
	Combined share			Combined share			Combined shares						Other combined						Non-controlling
	capitals			premiums			held in treasury			Translation reserve			reserves			Total			interests			Total equity
	€	m		€	m		€	m		€	m		€	m		€	m		€	m		€	m

Balance at 1 January 2012		268			3,268			(796	)		297			(431	)		2,606			30			2,636
Total comprehensive income for the year		–			–			–			(102	)		1,144			1,042			6			1,048
Dividends paid		–			–			–			–			(641	)		(641	)		(5	)		(646	)
Issue of ordinary shares, net of expenses		1			58			–			–			–			59			–			59
Repurchase of ordinary shares		–			–			(308	)		–			–			(308	)		–			(308	)
Increase in share based remuneration reserve		–			–			–			–			38			38			–			38
Settlement of share awards		–			–			9			–			(9	)		–			–			–
Acquisitions		–			–			–			–			–			–			11			11
Disposals of non-controlling interests		–			–			–			–			8			8			1			9
Exchange differences on translation of capital and reserves		5			28			(11	)		(34	)		12			–			(1	)		(1	)

Balance at 1 January 2013		274			3,354			(1,106	)		161			121			2,804			42			2,846
Total comprehensive income for the year		–			–			–			(171	)		1,386			1,215			6			1,221
Dividends paid		–			–			–			–			(648	)		(648	)		(7	)		(655	)
Issue of ordinary shares, net of expenses		1			147			–			–			–			148			–			148
Repurchase of ordinary shares		–			–			(708	)		–			–			(708	)		–			(708	)
Increase in share based remuneration reserve (net of tax)		–			–			–			–			57			57			–			57
Settlement of share awards		–			–			47			–			(47	)		–			–			–
Exchange differences on translation of capital and reserves		(6	)		(37	)		10			35			(2	)		–			(1	)		(1	)

Balance at 31 December 2013		269			3,464			(1,757	)		25			867			2,868			40			2,908

The Reed Elsevier condensed combined financial information (“the combined financial information”) represents the combined interests of the Reed Elsevier PLC and Reed Elsevier NV shareholders and encompasses the businesses of Reed Elsevier Group plc and Elsevier Reed Finance BV and their respective subsidiaries, associates and joint ventures, together with the two parent companies, Reed Elsevier PLC and Reed Elsevier NV (“Reed Elsevier” or “the combined businesses”).

The combined financial information, presented in condensed form, has been abridged from the audited combined financial statements for the year ended 31 December 2013, which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the European Union and as issued by the International Accounting Standards Board and on which the auditors have issued an unqualified opinion. The Reed Elsevier accounting policies under IFRS are set out in the Reed Elsevier Annual Reports and Financial Statements 2012 on pages 98 to 103. The combined financial information has been prepared in accordance with those accounting policies. Financial information is presented in both sterling and euros.

The directors of Reed Elsevier PLC and Reed Elsevier NV, having made appropriate enquiries, consider that adequate resources exist for the combined businesses to continue in operational existence for the foreseeable future and that, therefore, it is appropriate to adopt the going concern basis in preparing the combined financial information for the year ended 31 December 2013.

With effect from 1 January 2013, IAS19 Employee Benefits (revised) inter alia changes the methodology used in the calculation of the net pension financing credit or charge in relation to defined benefit pension schemes. Under the revised standard, pension asset returns included within the net pension financing credit or charge are calculated by reference to the discount rate of high quality corporate bonds (being also the discount rate applied in the calculation of pension obligations) and are no longer based on the expected returns on scheme assets. The effect is to reduce the asset returns recognised in the income statement.

Adoption of IAS19 (revised) has had no impact on Reed Elsevier’s combined statement of financial position and statement of cash flows. The net pension financing credit or charge is now presented within net finance costs in Reed Elsevier’s combined income statement, rather than within operating profit as previously reported. Given that the revised standard may introduce greater volatility to the income statement, the net pension financing credit or charge has been excluded from the adjusted figures used by Reed Elsevier as additional performance measures.

As required under the revised standard, comparative figures have been restated. For the year ended 31 December 2012, operating profits are £25m/€31m lower and net finance costs are £11m/€13m higher than previously reported. On an adjusted basis, profit before tax is £25m/€30m lower.

With effect from 1 January 2013 Reed Elsevier adopted IAS1 – Presentation of Items of Other Comprehensive Income – Amendments to IAS1. The standard amends the grouping of items presented in the statement of comprehensive income into items that may be reclassified to profit or loss in a future period and items that will never be reclassified.

With effect from 1 January 2013 Reed Elsevier also adopted IFRS10 Consolidated Financial Statements, IFRS11 Joint Arrangements, IFRS12 Disclosure of Interests in Other Entities, and IFRS13 Fair Value Measurement, in addition to amendments to IAS27 Consolidated and Separate Financial Statements and IAS28 Investments in Associates. Adoption of these new accounting standards and amendments has not had a significant impact on Reed Elsevier’s accounting policies or reporting. With the exception of IFRS13, these standards and amendments have been early adopted for the purposes of Reed Elsevier’s application of IFRS as adopted by the EU.

Reed Elsevier’s reported segments are based on the internal reporting structure and financial information provided to the Chief Executive Officer and Boards.

Reed Elsevier is a world leading provider of professional information solutions organised as five business segments: Scientific, Technical & Medical, providing information and tools to help its customers improve scientific and healthcare outcomes; Risk Solutions, providing tools that combine proprietary, public and third-party information with advanced technology and analytics; Business Information, providing data services, information and marketing solutions to business professionals; Legal, providing legal, tax, regulatory news & business information to legal, corporate, government, accounting and academic markets; and Exhibitions, organising exhibitions and conferences.

Adjusted operating profit is the key segmental profit measure used by Reed Elsevier in assessing performance. Adjusted operating profit is reconciled to reported figures in note 4.


			£				€
	2013		2012		2013		2012
	£	m	£	m	€	m	€	m

Business segment
Scientific, Technical & Medical		2,126		2,063		2,509		2,538
Risk Solutions		933		926		1,101		1,139
Business Information		547		663		645		815
Legal		1,567		1,610		1,849		1,980
Exhibitions		862		854		1,017		1,051

Total		6,035		6,116		7,121		7,523

Geographical origin
North America		3,103		3,122		3,661		3,840
United Kingdom		985		966		1,162		1,188
The Netherlands		656		611		774		752
Rest of Europe		698		788		824		969
Rest of world		593		629		700		774

Total		6,035		6,116		7,121		7,523

Geographical market
North America		3,082		3,154		3,637		3,879
United Kingdom		443		442		523		544
The Netherlands		166		165		196		203
Rest of Europe		1,074		1,176		1,267		1,447
Rest of world		1,270		1,179		1,498		1,450

Total		6,035		6,116		7,121		7,523


				£						€
				2012						2012
2013Restated								2013		Restated
	£	m		£	m		€	m		€	m

Business segment
Scientific, Technical & Medical		826			780			975			960
Risk Solutions		414			392			489			482
Business Information		107			119			126			146
Legal		238			234			281			288
Exhibitions		213			210			251			258

Subtotal		1,798			1,735			2,122			2,134
Corporate costs		(49	)		(47	)		(58	)		(58	)

Total		1,749			1,688			2,064			2,076


				£						€
				2012						2012
2013Restated								2013		Restated
	£	m		£	m		€	m		€	m

Business segment
Scientific, Technical & Medical		742			706			876			868
Risk Solutions		312			281			368			346
Business Information		71			76			84			93
Legal		139			146			164			180
Exhibitions		161			171			190			210

Subtotal		1,425			1,380			1,682			1,697
Corporate costs		(49	)		(47	)		(58	)		(58	)
Total		1,376			1,333			1,624			1,639

Reconciliation of operating profit before joint ventures to cash generated from operations


				£						€
				2012						2012
2013Restated								2013		Restated
	£	m		£	m		€	m		€	m

Operating profit before joint ventures		1,347			1,309			1,589			1,610
Amortisation of acquired intangible assets		317			328			374			404
Amortisation of internally developed intangible assets		160			151			189			186
Depreciation of property, plant and equipment		89			76			105			93
Share based remuneration		31			31			37			38

Total non cash items		597			586			705			721

Increase in working capital		(1	)		(48	)		(1	)		(59	)

Cash generated from operations		1,943			1,847			2,293			2,272


													£
							Related
	Cash &						derivative
	cash						financial
	equivalents			Borrowings			instruments			2013			2012
	£	m		£	m		£	m		£	m		£	m

At start of year		641			(3,892	)		124			(3,127	)		(3,433	)
Decrease in cash and cash equivalents		(532	)		–			–			(532	)		(72	)
Decrease in borrowings		–			586			(14	)		572			283
Changes in net borrowings resulting from cash flows		(532	)		586			(14	)		40			211

Inception of finance leases		–			(12	)		–			(12	)		(13	)
Fair value and other adjustments to borrowings and related derivatives		–			32			(33	)		(1	)		1
Exchange translation differences		23			5			–			28			107

At end of year		132			(3,281	)		77			(3,072	)		(3,127	)

													€
Related
Cash &							derivative
cash							financial
equivalents				Borrowings			instruments				2013			2012
	€	m		€	m		€	m		€	m		€	m

At start of year		788			(4,787	)		153			(3,846	)		(4,119	)
Decrease in cash and cash equivalents		(628	)		–			–			(628	)		(89	)
Decrease in borrowings		–			693			(17	)		676			349
Changes in net borrowings resulting from cash flows		(628	)		693			(17	)		48			260

Inception of finance leases		–			(14	)		–			(14	)		(16	)
Fair value and other adjustments to borrowings and related derivatives		–			38			(39	)		(1	)		1
Exchange translation differences		(2	)		133			(4	)		127			28

At end of year		158			(3,937	)		93			(3,686	)		(3,846	)

Net borrowings comprise cash and cash equivalents, loan capital, finance leases, promissory notes, bank and other loans, derivative financial instruments that are used to hedge the fair value of fixed rate borrowings and adjustments in respect of cash collateral received/paid.

Short term bank loans, overdrafts and commercial paper were backed up at 31 December 2013 by a $2,000m (£1,207m/€1,448m) committed bank facility maturing in July 2018, which was undrawn.

4 Adjusted figures
Reed Elsevier uses adjusted figures as additional performance measures. Adjusted operating profit excludes amortisation of acquired intangible assets, acquisition related costs and the share of taxes in joint ventures. Acquisition related costs relate to acquisition integration, transaction related fees, and those elements of deferred and contingent consideration required to be expensed under IFRS. Adjusted profit before tax also excludes disposal related and other non operating items and the net financing charge or credit on defined benefit pension schemes. The adjusted tax charge excludes the tax effect of these adjusting items, exceptional tax credits (in 2012 only) and movements on deferred tax assets and liabilities related to goodwill and acquired intangible assets. It includes the benefit of tax amortisation where available on goodwill and acquired intangible assets. Adjusted operating cash flow is measured after net capital expenditure and dividends from joint ventures but before payments in relation to prior year exceptional restructuring programmes and acquisition related costs. Adjusted figures are derived as follows:


				£						€
				2012						2012
2013Restated								2013		Restated
	£	m		£	m		€	m		€	m

Operating profit		1,376			1,333			1,624			1,639
Adjustments:
Amortisation of acquired intangible assets		318			329			375			405
Acquisition related costs		43			21			51			26
Reclassification of tax in joint ventures		12			5			14			6

Adjusted operating profit		1,749			1,688			2,064			2,076

Profit before tax		1,196			1,151			1,412			1,416
Adjustments:
Amortisation of acquired intangible assets		318			329			375			405
Net financing charge on defined benefit pension schemes		19			11			22			14
Acquisition related costs		43			21			51			26
Reclassification of tax in joint ventures		12			5			14			6
Disposals and other non operating items		(16	)		(45	)		(19	)		(56	)

Adjusted profit before tax		1,572			1,472			1,855			1,811

Tax charge		(81	)		(102	)		(96	)		(126	)
Adjustments:
Deferred tax movements on goodwill and acquired intangible assets		7			7			9			8
Tax on net financing charge on defined benefit pension schemes		(6	)		(3	)		(7	)		(4	)
Tax on acquisition related costs		(12	)		(5	)		(14	)		(6	)
Reclassification of tax in joint ventures		(12	)		(5	)		(14	)		(6	)
Tax on disposals and other non operating items		34			(58	)		40			(71	)
Other deferred tax credits from intangible assets*		(300	)		(84	)		(354	)		(103	)
Exceptional prior year tax credit		–			(96	)		–			(118	)
Adjusted tax charge		(370	)		(346	)		(436	)		(426	)

Net profit attributable to parent companies’ shareholders		1,110			1,044			1,310			1,284
Adjustments (post-tax):
Amortisation of acquired intangible assets		325			336			384			413
Net financing charge on defined benefit pension schemes		13			8			15			10
Acquisition related costs		31			16			37			20
Disposals and other non operating items		18			(103	)		21			(127	)
Other deferred tax credits from intangible assets*		(300	)		(84	)		(354	)		(103	)
Exceptional prior year tax credit		–			(96	)		–			(118	)
Adjusted net profit attributable to parent companies’ shareholders		1,197			1,121			1,413			1,379

movements on deferred tax liabilities arising on acquired intangible assets that do not qualify for tax amortisation and in 2013 non-recurring deferred tax credits arising on the alignment of certain business assets with their global management structure.


				£						€
	2013			2012			2013			2012
	£	m		£	m		€	m		€	m

Cash generated from operations		1,943			1,847			2,293			2,272
Dividends received from joint ventures		22			20			26			25
Purchases of property, plant and equipment		(57	)		(70	)		(67	)		(86	)
Proceeds from disposals of property, plant and equipment		6			7			7			9
Expenditure on internally developed intangible assets		(251	)		(263	)		(296	)		(323	)
Payments in relation to exceptional restructuring costs		12			25			14			30
Payments in relation to acquisition related costs		28			37			33			45

Adjusted operating cash flow		1,703			1,603			2,010			1,972

5 Pension schemes
The amount recognised in the statement of financial position in respect of defined benefit pension schemes at the start and end of the year and the movements during the year were as follows:


				£						€
				2012						2012
2013Restated								2013		Restated
	£	m		£	m		€	m		€	m

At start of year		(466	)		(242	)		(573	)		(290	)
Service cost (including settlement, past service and curtailment credits of £59m/€70m (2012: £20m/€25m))		(14	)		(43	)		(16	)		(53	)
Net financing charge on defined benefit pension schemes		(19	)		(11	)		(22	)		(14	)
Actuarial gains/(losses)		40			(293	)		47			(360	)
Contributions by employer		83			116			98			143
Exchange translation differences		(3	)		7			11			1

At end of year		(379	)		(466	)		(455	)		(573	)


				£						€
	2013			2012			2013			2012
	£	m		£	m		€	m		€	m

Fair value of scheme assets		3,981			3,806			4,777			4,682
Defined benefit obligations of funded schemes		(4,200	)		(4,112	)		(5,040	)		(5,058	)

Net deficit of funded schemes		(219	)		(306	)		(263	)		(376	)
Defined benefit obligations of unfunded schemes		(160	)		(160	)		(192	)		(197	)

Net deficit		(379	)		(466	)		(455	)		(573	)

6 Provisions
The amount recognised in the statement of financial position in respect of provisions at the start and end of the year and the movements during the period were as follows:

The amount as at 31 December 2013 comprises property provisions of £131m/€157m (2012: £164m/€202m), relating to sub-lease shortfalls and guarantees given in respect of certain property leases, and restructuring provisions of £2m/€2m (2012: £5m/€6m).

7 Related party transactions
There have been no significant related party transactions that have had a material impact on the performance or financial position of Reed Elsevier in the year ended 31 December 2013.

8 Exchange translation rates
In preparing the combined financial information the following exchange rates have been applied:

Condensed consolidated statement of comprehensive income
For the year ended 31 December 2013

Adjusted profit and earnings per share figures are presented in note 2 as additional performance measures.

Condensed consolidated statement of cash flows
For the year ended 31 December 2013


				£
	2013			2012
	£	m		£	m

Cash flows from operating activities
Cash used by operations		(2	)		(2	)
Interest received		10			1
Tax paid		(3	)		(2	)

Net cash from/(used in) operating activities		5			(3	)

Cash flows from investing activities
Dividends received from joint ventures		102			694
Net cash from investing activities		102			694

Cash flows from financing activities
Equity dividends paid		(278	)		(264	)
Repurchase of ordinary shares		(326	)		(143	)
Proceeds on issue of ordinary shares		50			33
Decrease/(increase) in net funding balances due from joint ventures		447			(317	)

Net cash used in financing activities		(107	)		(691	)

Movement in cash and cash equivalents		–			–


				£
	2013			2012
	£	m		£	m

Non-current assets
Investments in joint ventures		1,266			1,207

Total assets		1,266			1,207

Current liabilities
Taxation		2			1

Total liabilities		2			1

Net assets		1,264			1,206

Capital and reserves
Called up share capital		182			181
Share premium account		1,257			1,208
Shares held in treasury (including in joint ventures)		(752	)		(447	)
Capital redemption reserve		4			4
Translation reserve		40			87
Other reserves		533			173

Total equity		1,264			1,206

Condensed consolidated statement of changes in equity
For the year ended 31 December 2013

Shares held in

Capital redemption

Total

Share capital

Share premium

treasury

reserve

Translation reserve

Other reserves

equity

Balance at 1 January 2012

180

1,176

(308

)

159

(62

)

1,149

Total comprehensive income for the year

–

(72

)

478

406

Equity dividends paid

–

(264

)

(264

)

Issue of ordinary shares, net of expenses

–

Repurchase of ordinary shares

–

(143

)

–

(143

)

Share of joint ventures’ increase in share based remuneration reserve

–

Share of joint ventures’ settlement of share awards by the employee benefit trust

–

)

–

Share of joint ventures’ disposal of non-controlling interests

–

Equalisation adjustments

–

Balance at 1 January 2013

181

1,208

(447

)

173

1,206

Total comprehensive income for the year

–

(47

)

606

559

Equity dividends paid

–

(278

)

(278

)

Issue of ordinary shares, net of expenses

–

Repurchase of ordinary shares

–

(326

)

–

(326

)

Share of joint ventures’ increase in share based remuneration reserve (net of tax)

–

Share of joint ventures’ settlement of share awards by the employee benefit trust

–

(21

)

–

Equalisation adjustments

–

Balance at 31 December 2013

182

1,257

(752

)

533

1,264

The Reed Elsevier PLC share of the Reed Elsevier combined results has been calculated on the basis of the 52.9% economic interest of the Reed Elsevier PLC shareholders in the Reed Elsevier combined businesses, after taking account of the results arising in Reed Elsevier PLC and its subsidiary undertakings.

Reed Elsevier PLC’s 52.9% economic interest in the net assets of the combined businesses is shown in the statement of financial position as investments in joint ventures, net of the assets and liabilities reported as part of Reed Elsevier PLC and its subsidiary undertakings.

The summary financial information, presented in condensed form, has been abridged from the consolidated financial statements for the year ended 31 December 2013, which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the European Union and as issued by the International Accounting Standards Board, and are set out on page 158 of the Reed Elsevier Annual Reports and Financial Statements 2012. The auditors have reported on the consolidated financial statements of Reed Elsevier PLC. Their report was unqualified, did not draw attention to any matters of emphasis, and did not contain statements under s498(2) or (3) of the United Kingdom Companies Act 2006.

The directors of Reed Elsevier PLC, having made appropriate enquiries, consider that adequate resources exist for the group to continue in operational existence for the foreseeable future and that, therefore, it is appropriate to adopt the going concern basis in preparing the summary financial information for the year ended 31 December 2013.

As described on page 23, the combined businesses adopted IAS19 Employee Benefits (revised) with effect from 1 January 2013. As required under the revised standard, comparative figures have been restated. For the year ended 31 December 2012, Reed Elsevier PLC’s share of results of joint ventures is £14m lower and basic earnings per share is 1.2p lower than previously reported. On an adjusted basis, earnings per share is 0.7p lower than previously reported.

With effect from 1 January 2013, the combined business also adopted various other standards, interpretations and amendments to IFRS, none of which have had a significant impact on Reed Elsevier’s accounting policies or reporting.

2 Adjusted figures
Adjusted profit and earnings per share figures are used as additional performance measures. Adjusted earnings per share is based upon the Reed Elsevier PLC shareholders’ 52.9% economic interest in the adjusted net profit attributable of the Reed Elsevier combined businesses, which is reconciled to the reported figures in note 4 to the combined financial information. The adjusted figures are derived as follows:

Profit

attributable to

Basic earnings

ordinary shareholders

per share

2012

2013Restated

2013

Restated

£m£mpence

pence

Reported figures

572

538

48.8p

44.8p

Effect of tax credit equalisation on distributed earnings

1.3p

1.2p

Profit attributable to ordinary shareholders based on 52.9% economic interest in the Reed Elsevier combined businesses

587

552

50.1p

46.0p

Share of adjustments in joint ventures

3.9p

3.4p

Adjusted figures

633

593

54.0p

49.4p

The Directors of Reed Elsevier PLC have proposed a final dividend per ordinary share of 17.95p (2012: 17.0p). The cost of the final dividend, if approved by shareholders, is expected to be £208m. No liability has been recognised at the statement of financial position date. The Reed Elsevier PLC final dividend as approved will be paid on 23 May 2014, with ex-dividend and record dates of 30 April 2014 and 2 May 2014 respectively. Dividends paid to Reed Elsevier PLC and Reed Elsevier NV shareholders are, other than in special circumstances, equalised at the gross level inclusive of the UK tax credit received by certain Reed Elsevier PLC shareholders. The equalisation adjustment equalises the benefit of the tax credit between the two sets of shareholders in accordance with the equalisation agreement.

2013

2012

Shares in issue net

Shares in issue net

Shares in issue

Treasury shares

of treasury shares

of treasury shares

(millions)

(millions)

Number of ordinary shares

At start of year

1,257.6

(71.0

)

1,186.6

1,202.6

Issue of ordinary shares

9.4

–

9.4

6.7

Repurchase of ordinary shares

–

(41.9

)

(41.9

)

(23.3

)

Net release of shares by the employee benefit trust

–

3.3

0.6

At end of year

1,267.0

(109.6

)

1,157.4

1,186.6

Weighted average number of equivalent ordinary shares during the year

1,172.2

1,200.6

5 Contingent liabilities and related party transactions
There are contingent liabilities in respect of borrowings of joint ventures guaranteed jointly and severally by Reed Elsevier PLC and Reed Elsevier NV amounting to £3,063m at 31 December 2013 (2012: £3,595m).

There have been no significant related party transactions that have had a material impact on the performance or financial position of Reed Elsevier PLC in the year ended 31 December 2013.

Condensed consolidated statement of comprehensive income
For the year ended 31 December 2013

Adjusted profit and earnings per share figures are presented in note 2 as additional performance measures.

Condensed consolidated statement of cash flows
For the year ended 31 December 2013


				€
	2013			2012
	€	m		€	m

Cash flows from operating activities
Cash used by operations		(3	)		(5	)
Interest received		19			6
Tax paid		(1	)		(2	)

Net cash from/(used in) operating activities		15			(1	)

Cash flows from investing activities
Dividends received from joint ventures		186			754
Net cash from investing activities		186			754

Cash flows from financing activities
Equity dividends paid		(321	)		(319	)
Repurchase of shares		(337	)		(141	)
Proceeds on issue of ordinary shares		88			18
Decrease/(increase) in net funding balances due from joint ventures		370			(313	)

Net cash used in financing activities		(200	)		(755	)

Movement in cash and cash equivalents		1			(2	)


				€
	2013			2012
	€	m		€	m

Non-current assets
Investments in joint ventures		1,488			1,455
Current assets
Amounts due from joint ventures		4			4
Cash and cash equivalents		2			1

		6			5

Total assets		1,494			1,460

Current liabilities
Payables		6			7
Taxation		54			51

Total liabilities		60			58

Net assets		1,434			1,402

Capital and reserves
Share capital issued		55			54
Paid-in surplus		2,276			2,189
Shares held in treasury (including in joint ventures)		(881	)		(571	)
Translation reserve		(131	)		(42	)
Other reserves		115			(228	)

Total equity		1,434			1,402

Condensed consolidated statement of changes in equity
For the year ended 31 December 2013

€

Share

Shares held In

Total

capital

Paid-in surplus

treasury

Translation reserve

Other reserves

equity

€

Balance at 1 January 2012

2,171

(432

)

(496

)

1,303

Total comprehensive income for the year

–

(51

)

572

521

Equity dividends paid

–

(319

)

(319

)

Issue of ordinary shares, net of expenses

–

Repurchase of shares

–

(141

)

–

(141

)

Share of joint ventures’ increase in share based remuneration reserve

–

Share of joint ventures’ settlement of share awards by the employee benefit trust

–

)

–

Share of joint ventures’ disposal of non-controlling interests

–

Equalisation adjustments

–

)

Exchange translation differences

–

)

–

Balance at 1 January 2013

2,189

(571

)

(42

)

(228

)

1,402

Total comprehensive income for the year

–

(86

)

693

607

Equity dividends paid

–

(321

)

(321

)

Issue of ordinary shares, net of expenses

–

Repurchase of shares

–

(337

)

–

(337

)

Share of joint ventures’ increase in share based remuneration reserve (net of tax)

–

Share of joint ventures’ settlement of share awards by the employee benefit trust

–

(24

)

–

Equalisation adjustments

–

(34

)

(34

)

Exchange translation differences

–

)

–

Balance at 31 December 2013

2,276

(881

)

(131

)

115

1,434

The Reed Elsevier NV share of the Reed Elsevier combined results has been calculated on the basis of the 50% economic interest of the Reed Elsevier NV shareholders in the Reed Elsevier combined businesses, after taking account of the results arising in Reed Elsevier NV and its subsidiary undertakings.

Reed Elsevier NV’s 50% economic interest in the net assets of the combined businesses is shown in the statement of financial position as investments in joint ventures, net of the assets and liabilities reported as part of Reed Elsevier NV and its subsidiary undertakings.

The summary financial information, presented in condensed form, has been abridged from the consolidated financial statements for the year ended 31 December 2013, which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the European Union and as issued by the International Accounting Standards Board, and are set out on pages 178 to 179 of the Reed Elsevier Annual Reports and Financial Statements 2012. The auditors have reported on the consolidated financial statements of Reed Elsevier NV. Their report was unqualified, did not draw attention to any matters of emphasis, and did not contain statements under Article 2:395 of the Netherlands Civil Code.

The Board of Reed Elsevier NV, having made appropriate enquiries, consider that adequate resources exist for the group to continue in operational existence for the foreseeable future and that, therefore, it is appropriate to adopt the going concern basis in preparing the summary financial information for the year ended 31 December 2013.

As described on page 23, the combined businesses adopted IAS19 Employee Benefits (revised) with effect from 1 January 2013. As required under the revised standard, comparative figures have been restated. For the year ended 31 December 2012, Reed Elsevier NV’s share of results of joint ventures is €16m lower and basic earnings per share is €0.03 lower than previously reported. On an adjusted basis, earnings per share is €0.01 lower than previously reported.

2 Adjusted figures
Adjusted profit and earnings per share figures are used as additional performance measures. Adjusted earnings per share is based upon the Reed Elsevier NV shareholders’ 50% economic interest in the adjusted net profit attributable of the Reed Elsevier combined businesses, which is reconciled to the reported figures in note 4 to the combined financial information. The adjusted figures are derived as follows:

The Directors of Reed Elsevier NV have proposed a final dividend per ordinary share of €0.374 (2012: €0.337). The cost of the final dividend, if approved by shareholders, is expected to be €252m. No liability has been recognised at the statement of financial position date. The Reed Elsevier NV final dividend as approved will be paid on 23 May 2014, with ex-dividend dates of 30 April 2014 and 1 May 2014 and a record date of 5 May 2014. Dividends paid to Reed Elsevier PLC and Reed Elsevier NV shareholders are, other than in special circumstances, equalised at the gross level inclusive of the UK tax credit received by certain Reed Elsevier PLC shareholders. The equalisation adjustment equalises the benefit of the tax credit between the two sets of shareholders in accordance with the equalisation agreement.

2013

2012

Ordinary share

Ordinary share

equivalents

equivalents

net of

net of

Ordinary shares in

treasury

treasury

issue

R shares in issue

Treasury shares

shares

(millions)

(millions)

Number of ordinary shares or equivalents

At start of year

726.0

43.0

(44.2

)

724.8

735.8

Issue of ordinary shares

8.1

–

8.1

1.9

Repurchase of ordinary and R shares

–

(25.2

)

(25.2

)

(13.3

)

Net release of shares by the employee benefit trust

–

2.0

0.4

At end of year

734.1

43.0

(67.4

)

709.7

724.8

Weighted average number of equivalent ordinary shares during the year

717.6

734.0

The average number of equivalent ordinary shares takes into account the R shares in the company held by a subsidiary of Reed Elsevier PLC, which represent a 5.8% indirect interest in the company’s share capital.

At 31 December 2013 treasury shares included 156,394 R shares (2012: 62,341), equivalent to 1,563,940 (2012: 623,410) Reed Elsevier NV ordinary shares.

At 31 December 2013, 4,146,785 R shares (2012: 4,240,838) were held by a subsidiary of Reed Elsevier PLC. The R shares are convertible at the election of the holders into ten ordinary shares each and each R share carries an entitlement to cast ten votes. They have otherwise the same rights as the ordinary shares, except that Reed Elsevier NV may pay a lower dividend on the R shares.

5 Contingent liabilities and related party transactions
There are contingent liabilities in respect of borrowings of joint ventures guaranteed jointly and severally by Reed Elsevier NV and Reed Elsevier PLC amounting to €3,676m at 31 December 2013 (2012: €4,422m).

There have been no significant related party transactions that have had a material impact on the performance or financial position of Reed Elsevier NV in the year ended 31 December 2013.

This summary financial information in US dollars is a simple translation of the Reed Elsevier combined financial information into US dollars at the rates of exchange set out in note 8 to the combined financial information. The financial information provided below is prepared in accordance with accounting principles as used in the preparation of the Reed Elsevier combined financial information. It does not represent a restatement under US Generally Accepted Accounting Principles, which would be different in some significant respects.


			$
	2013		2012
	US$	m	US$	Restated m

Revenue		9,415		9,724
Operating profit		2,147		2,119
Profit before tax		1,866		1,830
Profit attributable to parent companies’ shareholders		1,732		1,660

Adjusted operating profit		2,728		2,684
Adjusted profit before tax		2,452		2,340
Adjusted profit attributable to parent companies’ shareholders		1,867		1,782

Basic earnings per American Depositary Share (ADS)	US$		US$
Reed Elsevier PLC (Each ADS comprises four ordinary shares)	$	3.05	$	2.85
Reed Elsevier NV (Each ADS comprises two ordinary shares)	$	2.40	$	2.24
Adjusted earnings per American Depositary Share (ADS)
Reed Elsevier PLC (Each ADS comprises four ordinary shares)	$	3.37	$	3.14
Reed Elsevier NV (Each ADS comprises two ordinary shares)	$	2.61	$	2.43

Adjusted earnings per American Depository Share is based on Reed Elsevier PLC shareholders’ 52.9% and Reed Elsevier NV shareholders’ 50% respective shares of the adjusted net profit attributable of the Reed Elsevier combined businesses. Adjusted figures are presented as additional performance measures and are reconciled to the reported figures at their sterling and euro amounts in note 4 to the combined financial information and in note 2 to the summary financial information of the respective parent companies.

Reed Elsevier Group plc is a world leading provider of professional information solutions. The group employs more than 28,000 people, including almost 14,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV; the combined market capitalisation of the two parent companies is approximately £19bn/€24bn. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

The Reed Elsevier Annual Reports and Financial Statements 2013 will be available on the Reed Elsevier website at www.reedelsevier.com from 11 March 2014. Copies of the Annual Reports and Financial Statements 2013 are expected to be posted to shareholders in Reed Elsevier PLC on 24 March 2014, and will be available to shareholders in Reed Elsevier NV on request. Copies of the 2013 Results Announcement are available to the public on the Reed Elsevier website and from the respective companies:


ENQUIRIES:	Colin Tennant (Investors)	Paul Abrahams (Media)
	+44 (0)20 7166 5751	+44 (0)20 7166 5724


					Statement of financial
	Income statement				position
	2013		2012		2013		2012
	£	m	£	m	€	m	€	m

Euro to sterling		1.18		1.23		1.20		1.23
US dollars to sterling		1.56		1.59		1.66		1.62
US dollars to euro		1.32		1.29		1.38		1.32


		£
		2012
	2013 pence	Restated pence

Basic earnings per share	48.8p	44.8p
Diluted earnings per share	48.2p	44.3p


			$
	2013		2012
US$m			US$m

Non-current assets		14,376		13,738
Current assets		3,011		3,264
Assets held for sale		35		481

Total assets		17,422		17,843

Current liabilities		6,395		6,347
Non-current liabilities		7,000		7,591
Liabilities associated with assets held for sale		5		156
Total liabilities		13,400		14,094

Net assets		4,022		3,749


				£						€
	Year ended 31 December						Year ended 31 December
	New			Old			New			Old
	method			method			method			method
	2013			2013			2013			2013
	£	m		£	m		€	m		€	m

Adjusted operating profit
Scientific, Technical & Medical		787			826			929			975
Risk Solutions		401			414			473			489
Business Information		106			107			125			126
Legal		250			238			295			281
Exhibitions		210			213			248			251
Unallocated items		(5	)		(49	)		(6	)		(58	)
		1,749			1,749			2,064			2,064


				£
				2012
2013Restated
	£	m		£	m

Administrative expenses		(2	)		(2	)
Effect of tax credit equalisation on distributed earnings		(15	)		(14	)
Share of results of joint ventures		583			547

Operating profit		566			531
Finance income		10			1

Profit before tax		576			532
Tax (expense)/credit		(4	)		6

Profit attributable to ordinary shareholders		572			538


Notes to the consolidated financial information
	1	Basis of preparation


				€
				2012
2013Restated
	€	m		€	m

Profit attributable to shareholders		655			642
Share of joint ventures’ other comprehensive loss for the year		(48	)		(121	)
Total comprehensive income for the year		607			521


		€
		2012
	2013 €	Restated €

Basic earnings per share	€0.91	€0.87
Diluted earnings per share	€0.90	€0.87


		€
	2013	2012
	€	€

Ordinary shares
Interim (paid)	€0.132	€0.130
Final (proposed)	€0.374	€0.337

Total	€0.506	€0.467

R shares	–	–


Reed Elsevier PLC		Reed Elsevier NV
1-3 Strand London WC2N 5JR United Kingdom		Radarweg 29 1043 NX Amsterdam The Netherlands